UNSPSC 51352012: Ethinyl estradiol or ethinylestradiol

This classification denotes a therapeutic estradiol, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 423D2T571U. European Medicines Agency schedules Ethinyl estradiol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07277MIG. Ethinylestradiol generally arises in the molecular formula C20H24O2. The term 'ethinylestradiol' is a European Medicines Agency European Public Assessment Report System designation.

ETHINYLESTRADIOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Ethinyl estradiol bears US NLM identifiers UMLS ID C0015011 and NCI Concept Code C486. SMILES: OC1(C2(C(C3C(CC2)c2c(CC3)cc(O)cc2)CC1)C)C#C.

UNSPSC 51352012 Ethinyl estradiol or ethinylestradiol is a Commodity code covering a synthetic estrogen compound used primarily in oral contraceptive formulations and hormone replacement therapies. State and local governments procure this active pharmaceutical ingredient through their health departments, public health agencies, family planning clinics, and correctional health services to supply contraceptive medications to eligible populations, including low-income women, incarcerated individuals, and underserved communities. Issuing bodies include state health departments, county public health offices, and independent correctional facilities that maintain their own pharmaceutical procurement and supply chains. The work involves purchasing pharmaceutical-grade ethinyl estradiol in bulk quantities or finished-form contraceptive tablets, often subject to FDA compliance, pharmaceutical quality standards, and competitive bidding through state purchasing cooperatives or direct RFQ processes.

The source provides no recent state and local contract opportunities posted under this code. Without posted RFPs, RFQs, IBFs, or ITBs naming the code, recent issuing bodies, response dates, or geographic concentration, no representative solicitations can be identified. State and local procurement activity in pharmaceutical ingredients and contraceptive supplies tends to consolidate through state health department purchasing and cooperative agreements rather than frequent competitive postings, so absence of recent opportunity records does not necessarily indicate inactive demand.